An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
Clinical trial NCT02775903 · COMPLETED
Trial details
- NCT number
- NCT02775903
- Sponsor
- Celgene
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-03
- Primary completion
- 2018-12-31
- Enrollment
- 213
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.